Novasep Adds Small-Scale Manufacturing Capability to US Facility

Article

Novasep is building a new synthesis laboratory and adding capacity for kilogram-scale batches of synthetic molecules that are needed for biological testing and preclinical trials, at its Pennsylvania, US facility.

Novasep is building a new synthesis laboratory and adding kilogram-scale production at its existing US facility in Boothwyn, PA, the French company said in a Jan. 28, 2016 press release. This extension will allow Novasep to offer both chemistry and purification services and to produce the initial kilogram-scale batches of synthetic molecules that are needed for biological testing and preclinical trials.

The investment is in response to increasing demand from US customers for closer proximity to Novasep’s contract manufacturing services for early-stage development and production scale-up. Novasep has provided purification development services to North American customers for more than 15 years at this location. The new laboratory, equipped with reactors up to 50 L in size, will start operations in May 2016. It will offer cryogenic capacities and standard chemistry, as well as preparative purification chromatography processes.

Source: Novasep 

Recent Videos
Preeya Beczek, managing director and co-founder of Beczek.COM, chats about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
William K. Oh, MD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2025 MJH Life Sciences

All rights reserved.